Autopsy report · NCT02008994

Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer

“Resignation of Principal Investigator”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 4 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Sanford Health

Sponsor type

University, hospital or other

Conditions

Metastatic Breast Cancer

Interventions

Genomic and Proteomic Profiling

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Assessment of Emotional Memory During Transient Global Amnesia
  “Departure of the principal investigator” (88% match in meaning)
• "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot Study to Assess the Value of Written Information Documents.
  “Principal Investigator's departure” (86% match in meaning)
• Interest of Virtual Reality for the Management of Hospitalized Pregnant Patients at Risk of Preterm Delivery
  “departure of the principal investigator without replacement” (85% match in meaning)
• Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
  “Principal Investigator has left the institution” (84% match in meaning)
• Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia
  “Principal investigator left the institution” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.